CA1043208A - Dispensing lung contacting powdered medicaments - Google Patents
Dispensing lung contacting powdered medicamentsInfo
- Publication number
- CA1043208A CA1043208A CA194,459A CA194459A CA1043208A CA 1043208 A CA1043208 A CA 1043208A CA 194459 A CA194459 A CA 194459A CA 1043208 A CA1043208 A CA 1043208A
- Authority
- CA
- Canada
- Prior art keywords
- container
- aerosol
- button
- chamber
- mouthpiece
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 210000004072 lung Anatomy 0.000 title abstract description 20
- 239000000443 aerosol Substances 0.000 claims abstract description 54
- 239000002245 particle Substances 0.000 claims abstract description 23
- 239000003380 propellant Substances 0.000 claims description 27
- BDLFTHFBZRBSSL-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;n,n-diethyl-4-methylpiperazine-1-carboxamide Chemical compound CCN(CC)C(=O)N1CCN(C)CC1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 BDLFTHFBZRBSSL-UHFFFAOYSA-N 0.000 claims description 9
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 8
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 7
- 239000004479 aerosol dispenser Substances 0.000 claims description 6
- 239000000428 dust Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims 2
- 239000000843 powder Substances 0.000 abstract description 12
- 230000009885 systemic effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 230000000699 topical effect Effects 0.000 abstract 1
- 239000007921 spray Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000007600 charging Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 229910001220 stainless steel Inorganic materials 0.000 description 8
- 239000010935 stainless steel Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000005909 Kieselgur Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 230000000994 depressogenic effect Effects 0.000 description 5
- 229960003974 diethylcarbamazine Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- PGNKBEARDDELNB-UHFFFAOYSA-N Diethylcarbamazine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)C(=O)N1CCN(C)CC1 PGNKBEARDDELNB-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 229960004837 diethylcarbamazine citrate Drugs 0.000 description 1
- YGLLICRFEVEWOZ-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate Chemical compound [Na+].[Na+].C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 YGLLICRFEVEWOZ-UHFFFAOYSA-L 0.000 description 1
- DNQSGXVJKQBSMT-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate;hydrate Chemical compound O.[Na+].[Na+].C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3[O-])C(=O)O)=C([O-])C(C(O)=O)=CC2=C1 DNQSGXVJKQBSMT-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US00374176A US3809294A (en) | 1973-06-27 | 1973-06-27 | Dispensing lung contacting powdered medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1043208A true CA1043208A (en) | 1978-11-28 |
Family
ID=23475640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA194,459A Expired CA1043208A (en) | 1973-06-27 | 1974-03-08 | Dispensing lung contacting powdered medicaments |
Country Status (24)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3998226A (en) * | 1975-09-22 | 1976-12-21 | Edward G. Gomez | Inhalation device for encapsulated concentrates |
| US3994421A (en) * | 1975-09-29 | 1976-11-30 | American Cyanamid Company | Unitary therapeutic aerosol dispenser |
| SE408265B (sv) * | 1975-12-12 | 1979-06-05 | Draco Ab | Anordning for koldioxiddriven endosaerosol, avsedd for inhalering |
| GR69682B (enrdf_load_stackoverflow) * | 1978-09-11 | 1982-07-08 | Newhouse Michael T | |
| DE3348370C2 (de) * | 1982-10-08 | 2001-10-11 | Glaxo Group Ltd | Medikamenten-Packung und Verfahren zur Erzeugung eines zur Inhalation bestimmten Medikamenten-Pulver-Luftstroms |
| IT1217890B (it) * | 1988-06-22 | 1990-03-30 | Chiesi Farma Spa | Dispositivo per l'inalazione di aerosol dosati |
| US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
| US5040527A (en) * | 1990-12-18 | 1991-08-20 | Healthscan Products Inc. | Metered dose inhalation unit with slide means |
| US5186164A (en) * | 1991-03-15 | 1993-02-16 | Puthalath Raghuprasad | Mist inhaler |
| US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
| AU663905B2 (en) | 1991-12-12 | 1995-10-26 | Glaxo Group Limited | Medicaments |
| US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| US5683676A (en) * | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| US5674471A (en) * | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
| US5744123A (en) * | 1991-12-12 | 1998-04-28 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
| WO1993011745A1 (en) * | 1991-12-12 | 1993-06-24 | Glaxo Group Limited | Medicaments |
| US5916540A (en) | 1994-10-24 | 1999-06-29 | Glaxo Group Limited | Aerosol formulations containing P134A and/or P227 and particulate medicament |
| EP1086688B1 (en) * | 1991-12-18 | 2004-03-03 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| US7101534B1 (en) | 1991-12-18 | 2006-09-05 | 3M Innovative Properties Company | Suspension aerosol formulations |
| GB9322014D0 (en) * | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US5839429A (en) * | 1994-03-25 | 1998-11-24 | Astra Aktiebolag | Method and apparatus in connection with an inhaler |
| US5598836A (en) * | 1995-05-26 | 1997-02-04 | Healthscan Products, Inc. | Metered dose inhalation unit with slide means |
| US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| DE19740617A1 (de) * | 1997-09-16 | 1999-03-18 | Palas Gmbh | Verfahren und Vorrichtung zum Erzeugen eines Feststoff-Aerosols |
| US6293279B1 (en) | 1997-09-26 | 2001-09-25 | Trudell Medical International | Aerosol medication delivery apparatus and system |
| US6345617B1 (en) | 1997-09-26 | 2002-02-12 | 1263152 Ontario Inc. | Aerosol medication delivery apparatus and system |
| WO2001076671A2 (en) | 2000-04-11 | 2001-10-18 | Trudell Medical International | Aerosol delivery apparatus with positive expiratory pressure capacity |
| EP1381417A4 (en) * | 2001-04-26 | 2009-12-30 | New England Pharm Inc | DEVICE FOR RELEASING SATISFIED DOSHES OF LIQUID AND POWDERY MEDIUM |
| GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
| US7582284B2 (en) * | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
| US20030205226A1 (en) | 2002-05-02 | 2003-11-06 | Pre Holding, Inc. | Aerosol medication inhalation system |
| US6904908B2 (en) | 2002-05-21 | 2005-06-14 | Trudell Medical International | Visual indicator for an aerosol medication delivery apparatus and system |
| AU2004272077A1 (en) * | 2003-09-10 | 2005-03-24 | Map Pharmaceuticals, Inc. | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| CA2616997C (en) * | 2004-09-13 | 2014-12-23 | Oriel Therapeutics, Inc. | Dry powder inhalers that inhibit agglomeration, related devices and methods |
| NL1027255C2 (nl) * | 2004-10-15 | 2006-04-19 | Lab Tickner Ag | Inrichting voor het verwijderen van een teek. |
| EP2425820B1 (en) * | 2007-02-11 | 2015-04-08 | MAP Pharmaceuticals Inc | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
| US20110171141A1 (en) * | 2009-06-26 | 2011-07-14 | Kellerman Donald J | Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
| CA151549S (en) | 2013-02-14 | 2014-06-04 | Clement Clarke Int Ltd | Spacer for an asthma inhaler |
| WO2015006639A1 (en) | 2013-07-12 | 2015-01-15 | SILVA, John, H. | Mouthpiece for inhalers |
| USD748242S1 (en) * | 2014-07-11 | 2016-01-26 | H. Stuart Campbell | Inhaler mouthpiece |
| KR20230116786A (ko) * | 2020-12-01 | 2023-08-04 | 리버스피에이에이치 엘엘씨 | 만성 폐쇄성 폐질환, 천식, 폐렴, 기관지염, 낭포성 섬유증, 폐부종, 간질성 폐 질환, 사르코이드증, 특발성 폐섬유증, 급성 호흡곤란 증후군 및 폐동맥 고혈압을 치료하기 위한 방법 및 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE555972A (enrdf_load_stackoverflow) * | 1956-03-21 | |||
| US2890697A (en) * | 1957-03-15 | 1959-06-16 | Wilton E Van Sickle | Enclosed medicament container and atomizer |
| US3012555A (en) * | 1959-05-18 | 1961-12-12 | Meshberg Philip | Dispensing package for material under pressure |
| US3183907A (en) * | 1962-06-25 | 1965-05-18 | Merck & Co Inc | Device for inhalation aerosol |
| JPS4214552Y1 (enrdf_load_stackoverflow) * | 1964-12-30 | 1967-08-18 | ||
| JPS4514212Y1 (enrdf_load_stackoverflow) * | 1966-11-02 | 1970-06-16 | ||
| US3559851A (en) * | 1969-05-27 | 1971-02-02 | Valve Corp Of America | Fully-emptying valve assemblage |
| JPS566680Y2 (enrdf_load_stackoverflow) * | 1972-04-19 | 1981-02-13 |
-
1973
- 1973-06-27 US US00374176A patent/US3809294A/en not_active Expired - Lifetime
-
1974
- 1974-03-08 CA CA194,459A patent/CA1043208A/en not_active Expired
- 1974-03-12 ZA ZA00741633A patent/ZA741633B/xx unknown
- 1974-03-12 IL IL44401A patent/IL44401A/en unknown
- 1974-03-19 IE IE574/74A patent/IE40616B1/xx unknown
- 1974-03-21 GB GB1270674A patent/GB1471917A/en not_active Expired
- 1974-03-21 PH PH15648A patent/PH11643A/en unknown
- 1974-03-28 AR AR253017A patent/AR198562A1/es active
- 1974-03-29 DE DE2415360A patent/DE2415360C2/de not_active Expired
- 1974-04-02 IT IT49957/74A patent/IT1003994B/it active
- 1974-04-04 NL NLAANVRAGE7404626,A patent/NL178655C/xx not_active IP Right Cessation
- 1974-04-08 DD DD177768A patent/DD125188A5/xx unknown
- 1974-04-09 BE BE143026A patent/BE813512A/xx not_active IP Right Cessation
- 1974-04-09 YU YU00989/74A patent/YU36435B/xx unknown
- 1974-04-09 SU SU2017264A patent/SU537614A3/ru active
- 1974-04-10 AT AT299974A patent/AT342211B/de not_active IP Right Cessation
- 1974-04-10 FR FR7412670A patent/FR2234905B1/fr not_active Expired
- 1974-04-10 JP JP49041581A patent/JPS6010737B2/ja not_active Expired
- 1974-04-11 SE SE7405022A patent/SE405448B/xx unknown
- 1974-04-23 CH CH555174A patent/CH577832A5/xx not_active IP Right Cessation
- 1974-06-25 PL PL1974172163A patent/PL89980B1/pl unknown
- 1974-06-26 DK DK343874A patent/DK152967C/da not_active IP Right Cessation
- 1974-06-27 CS CS7400004539A patent/CS182257B2/cs unknown
- 1974-06-27 ES ES427755A patent/ES427755A1/es not_active Expired
-
1975
- 1975-10-13 CH CH1325075A patent/CH620207A5/de not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1043208A (en) | Dispensing lung contacting powdered medicaments | |
| US3895111A (en) | Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate | |
| AU666979B2 (en) | Powder inhaler | |
| US5239993A (en) | Dosage inhalator providing optimized compound inhalation trajectory | |
| EP1019127B1 (en) | Aerosol medication delivery apparatus | |
| EP0015247B1 (en) | An aerosol inhalation device | |
| CA1038346A (en) | Unitary therapeutic aerosol dispenser | |
| US4570630A (en) | Medicament inhalation device | |
| EP0773807B1 (en) | Inhalation device | |
| US20080190424A1 (en) | Unit dose dry powder inhaler | |
| EP0079478A1 (en) | Medicament inhalation device | |
| JPS61500831A (ja) | 吸入装置 | |
| AU2018204860B2 (en) | Inhalable medicaments | |
| IE45837B1 (en) | Device for use with pressurised aerosol type medicinal inhalation devices | |
| CA2396273C (en) | Aerosol inhaler | |
| EP0774986B1 (en) | Inhaler apparatus with optimisation chamber | |
| JP2004503492A (ja) | アルファ４−インテグリンアンタゴニスト含有の吸入用乾燥粉末状医薬製剤 | |
| HK40017650A (en) | Inhalable medicaments | |
| NZ721338B2 (en) | Inhalable medicaments | |
| MXPA06006284A (en) | Portable gas operating inhaler |